Infections associated with CAR ‐T cell therapy in patients with relapsed refractory multiple myeloma: Risks and prevention strategies

Documenti analoghi

• Efficacy and side effects of anti‐CD19 CAR T‐cell therapy in patients with relapsed/refractory gastrointestinal lymphoma
  di: Yi Li Jiang, et al.
  Pubblicazione: (2024)
• Clinical outcomes of pomalidomide‐based and daratumumab‐based therapies in patients with relapsed/refractory multiple myeloma: A real‐world cohort study in China
  di: Xiaoyan Han, et al.
  Pubblicazione: (2024)
• CAR T‐cell therapy shows impressive outcomes for patients with refractory multiple myeloma
  di: Mary Beth Nierengarten
  Pubblicazione: (2025)
• A real‐world retrospective–prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience
  di: Anna Furlan, et al.
  Pubblicazione: (2024)
• Several factors that predict the outcome of large B‐cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T‐cell therapy can be identified before cell administration
  di: Alice Sýkorová, et al.
  Pubblicazione: (2024)